Blockade of the CD47/SIRPα checkpoint axis potentiates the macrophage-mediated antitumor efficacy of tafasitamab.
Biedermann A, Patra-Kneuer M, Mougiakakos D, Büttner-Herold M, Mangelberger-Eberl D, Berges J, Kellner C, Altmeyer S, Bittenbring JT, Augsberger C, Ilieva-Babinsky K, Haskamp S, Beier F, Lischer C, Vera J, Lührmann A, Bertz S, Völkl S, Jacobs B, Steidl S, Mackensen A, Bruns H.
Biedermann A, et al. Among authors: bertz s.
Haematologica. 2024 Dec 1;109(12):3928-3940. doi: 10.3324/haematol.2023.284795.
Haematologica. 2024.
PMID: 38934068
Free PMC article.